Claims for Patent: 8,754,123

Summary for Patent: 8,754,123

Title:	Pharmaceutical compositions having desirable bioavailability
Abstract:	The present invention is directed to the provision of pharmaceutical compositions. The compositions include a therapeutic agent and a relatively low amount of surfactant for providing higher bioavailability of the therapeutic agent. The compositions are particularly desirable as ophthalmic compositions in which the therapeutic agent is a prostaglandin such as travoprost and the surfactant is a vegetable oil such as castor oil.
Inventor(s):	Kabra; Bhagwati P. (Euless, TX)
Assignee:	Alcon Research, Ltd. (Fort Worth, TX)
Application Number:	13/442,475
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,754,123
Patent Claims:	1. An aqueous ophthalmic pharmaceutical solution composition suitable for topical application to an eye of a human, comprising: a prostaglandin suitable for lowering intraocular pressure of the eye, the prostaglandin being in the composition at a concentration that is at least 0.001 w/v % but less than 0.01 w/v %; a surfactant in the composition at a concentration that is at least 0.03 w/v % but less than 0.3 w/v %, wherein: i. the surfactant is entirely ethoxylated and/or hydrogenated vegetable oil and the ethoxylated and/or hydrogenated castor oil is the only surfactant in the composition; and ii. the composition is free of benzalkonium chloride; and a polymeric quaternary ammonium compound in the composition at a concentration that is greater than 0.0003 w/v % but less than 0.003 w/v %; and water. 2. A composition as in claim 1 wherein concentration of the surfactant in the composition is less than 0.15 w/v %. 3. A composition as in claim 1 wherein the prostaglandin is travoprost. 4. A composition as in claim 1 wherein the prostaglandin and the surfactant are non-ionic. 5. A composition as in claim 1 wherein the surfactant is entirely ethoxylated or hydrogenated vegetable oil. 6. A composition as in claim 1 wherein the surfactant is entirely castor oil. 7. A composition as in claim 1 wherein the surfactant is entirely Polyoxyl 40 Hydrogenated castor Oil. 8. A composition as in claim 1 wherein the composition satisfies Ph. Eur. A, Ph. Eur. B or both. 9. A composition as in claim 1 wherein the composition is substantially free of any chloride containing agents. 10. A composition as in claim 1 wherein the prostaglandin is in the composition at a concentration of less than 0.006 w/v %. 11. A composition as in claim 1 wherein the composition is disposed in an eye dropper. 12. A composition as in claim 4 wherein the surfactant is entirely ethoxylated and/or hydrogenated vegetable oil. 13. A composition as in claim 12 wherein the surfactant is entirely castor oil. 14. A composition as in claim 13 wherein the prostaglandin is in the composition at a concentration of less than 0.006 w/v %. 15. A composition as in claim 14 wherein the composition satisfies Ph. Eur. A, Ph. Eur. B or both. 16. A composition as in claim 14 wherein the prostaglandin is travoprost. 17. A composition as in claim 16 wherein the surfactant is entirely Polyoxyl 40 Hydrogenated castor Oil. 18. A composition as in claim 17 wherein the composition is disposed in an eye dropper. 19. A composition as in claim 18 wherein concentration of the surfactant in the composition is less than 0.15 w/v %. 20. A composition as in claim 18 wherein concentration of the polymeric quaternary ammonium compound in the composition is greater than 0.0007 w/v % but less than 0.0015 w/v % of the pharmaceutical composition. 21. A composition as in claim 1 wherein concentration of the polymeric quaternary ammonium compound in the composition is greater than 0.0007 w/v % but less than 0.0015 w/v % of the pharmaceutical composition. 22. A composition as in claim 1 wherein the polymeric quaternary ammonium compound is polyquaternium-1. 23. A composition as in claim 20 wherein the polymeric quaternary ammonium compound is polyquaternium-1.